SINOPHARM GROUP 1/5/O.N.
Sinopharm Group Co. Ltd., together with its subsidiaries, engages in the wholesale and retail of pharmaceutical and healthcare products, and medical devices in the People's Republic of China. The company operates through four segments: Pharmaceutical Distribution, Medical Devices Distribution, Retail Pharmacy, and Other Business. The Pharmaceutical Distribution segment distributes pharmaceutical … Read more
SINOPHARM GROUP 1/5/O.N. (X2S1) - Net Assets
Latest net assets as of : €- EUR
Based on the latest financial reports, SINOPHARM GROUP 1/5/O.N. (X2S1) has net assets worth €- EUR as of .
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€-) and total liabilities (€-). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €- |
| % of Total Assets | 0% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | N/A |
SINOPHARM GROUP 1/5/O.N. - Net Assets Trend (None–None)
This chart illustrates how SINOPHARM GROUP 1/5/O.N.'s net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for SINOPHARM GROUP 1/5/O.N. (None–None)
The table below shows the annual net assets of SINOPHARM GROUP 1/5/O.N. from None to None.
| Year | Net Assets | Change |
|---|---|---|
| No yearly data available. | ||
Equity Component Analysis
This analysis shows how different components contribute to SINOPHARM GROUP 1/5/O.N.'s total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- No equity composition insights available.
SINOPHARM GROUP 1/5/O.N. Competitors by Market Cap
The table below lists competitors of SINOPHARM GROUP 1/5/O.N. ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Henry Schein Inc
NASDAQ:HSIC
|
$7.35 Billion |
|
Neles Oyj
HE:METSO_old
|
$7.35 Billion |
|
MTN Group Ltd PK
PINK:MTNOY
|
$7.35 Billion |
|
FirstCash Inc
NASDAQ:FCFS
|
$7.36 Billion |
|
Vaxcyte Inc
NASDAQ:PCVX
|
$7.34 Billion |
|
Xero Ltd
AU:XRO
|
$7.33 Billion |
|
Klépierre SA
PINK:KLPEF
|
$7.33 Billion |
|
YPF Sociedad Anonima
NYSE:YPF
|
$7.33 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in SINOPHARM GROUP 1/5/O.N.'s equity between the two most recent reporting periods.
Insufficient data available to analyze equity growth attribution.
Book Value vs Market Value Analysis
This analysis compares SINOPHARM GROUP 1/5/O.N.'s book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Insufficient data available to analyze book value vs market value.
Capital Efficiency Dashboard
This dashboard shows how efficiently SINOPHARM GROUP 1/5/O.N. utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Insufficient data available to analyze capital efficiency metrics.
Industry Comparison
This section compares SINOPHARM GROUP 1/5/O.N.'s net assets metrics with peer companies in the Medical Distribution industry.
Industry Context
- Industry: Medical Distribution
- Average net assets among peers: $1,192,244,105,699
- Average return on equity (ROE) among peers: -83.41%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| SINOPHARM GROUP 1/5/O.N. (X2S1) | €- | N/A | N/A | $7.34 Billion |
| KIMIA FARMA -B- (HQP) | $5.89 Trillion | 5.13% | 1.93x | $78.59 Million |
| Asker Healthcare Group AB (I88) | $3.50 Billion | 10.28% | 2.75x | $1.37 Billion |
| Paragon Care Limited (PXS) | $18.21 Million | 5.96% | 0.48x | $52.86 Million |
| TELES Informationstechnologien AG (TLIK) | $379.23K | -446.97% | 3.69x | $801.14K |
| Sinopharm Group Co. Ltd (X2S) | $68.28 Billion | 8.55% | 2.45x | $3.27 Billion |